Rodyti trumpą aprašą

dc.contributor.authorMalinauskienė, Vaidota
dc.contributor.authorZuzo, Anastasija
dc.contributor.authorLiakina, Valentina
dc.contributor.authorKazėnaitė, Edita
dc.contributor.authorStundienė, Ieva
dc.date.accessioned2023-12-22T07:05:50Z
dc.date.available2023-12-22T07:05:50Z
dc.date.issued2023
dc.identifier.issn2307-8960
dc.identifier.other(WOS_ID)001048419800003
dc.identifier.urihttps://etalpykla.vilniustech.lt/xmlui/handle/123456789/153544
dc.description.abstractInflammatory bowel disease (IBD) is a chronic condition that affects young individuals in their reproductive years. It may have long-term implications on their reproductive, sexual, and mental health. IBD has been related to menstrual abnormalities. Furthermore, the administration of biological therapy can also result in gynecological issues in addition to the disease itself. The purpose of this review was to present potential menstrual cycle problems in patients with IBD, as well as the impact of adalimumab and other anti-tumor necrosis factor medications on gynecological pathologyeng
dc.formatPDF
dc.format.extentp. 4989-4995
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyPubMed
dc.source.urihttps://www.wjgnet.com/2307-8960/full/v11/i21/4989.htm
dc.titleMenstrual cycle abnormalities in women with inflammatory bowel disease and effects of biological therapy on gynecological pathology
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.accessRightsThis article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/.
dcterms.licenseCreative Commons – Attribution – NonCommercial – 4.0 International
dcterms.references33
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionVilniaus universitetas
dc.contributor.institutionVilniaus universitetas Vilniaus Gedimino technikos universitetas
dc.contributor.facultyFundamentinių mokslų fakultetas / Faculty of Fundamental Sciences
dc.subject.researchfieldM 001 - Medicina / Medicine
dc.subject.researchfieldN 004 - Biochemija / Biochemistry
dc.subject.vgtuprioritizedfieldsFM0202 - Ląstelių ir jų biologiškai aktyvių komponentų tyrimai / Investigations on cells and their biologically active components
dc.subject.ltspecializationsL105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies
dc.subject.enmenstrual disorders
dc.subject.eninflammatory bowel disease
dc.subject.enadalimumab
dc.subject.eninfliximab
dc.subject.enanti-tumor necrosis factor-& alpha
dcterms.sourcetitleWorld journal of clinical cases
dc.description.issueiss. 21
dc.description.volumevol. 11
dc.publisher.nameBaishideng Publishing Group Inc.
dc.publisher.cityPleasanton
dc.identifier.doi001048419800003
dc.identifier.doi151666125
dc.identifier.doi37583859
dc.identifier.doi10.12998/wjcc.v11.i21.4989
dc.identifier.elaba175406231


Šio įrašo failai

FailaiDydisFormatasPeržiūra

Su šiuo įrašu susijusių failų nėra.

Šis įrašas yra šioje (-se) kolekcijoje (-ose)

Rodyti trumpą aprašą